The United Kingdom recorded its second-highest level of venture capital funding for life sciences during the first nine months of 2026, totaling £3.63 billion ($4.78 billion), surpassed only by 2021, according to Knight Frank’s “Q3 2026 UK Science & Innovation” report.
Third-quarter life sciences venture capital funding totaled £571.55 million ($752.7 million), down 75 percent from £2.31 billion ($3.04 billion) in the second quarter but up 13 percent year over year. Isomorphic Labs’ £1.6 billion ($2.11 billion) deal accounted for 69 percent of the second-quarter total, while pharmaceutical and biotechnology companies raised £400.57 million ($527.6 million), or 70 percent of third-quarter funding. Other life sciences companies raised £170.98 million ($225.2 million).
Knight Frank data shows that 499,711 square feet of life sciences space was leased across the English markets of Oxford, Cambridge and London in the first nine months of 2026, 12.1 percent